 |
Keyword Search |
 |
|
|
| |
|
|
|
Return to American Society of Addiction Medicine Events Library Menu
Showing sessions 1 - 10 of (33) TOTAL sessions
(PREV 10) 1 2 3 4 (NEXT 10)
|
|
Event : ASAM5 |
|
Session : ASAM801
COMPONENT SESSION I
Understanding and Employing Twelve-Step Groups in the Management of Addicted Patients; sponsored by the Action Group on Twelve-Step Recovery
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 13.5 MB
|
Download Format(s) :
MP3 | 
|
|
|
- Component Chair: Marc Galanter, MD
|
- Speakers: Marc Galanter, MD; Richard Ries, MD; Penelope Ziegler, MD
|
- Component Description: Patients often experience difficulty in
appreciating the value of attending a Twelve-Step program to
address their addictive problems. They may not make full use of
the modality, even though it could be invaluable to their recovery.
The panelists, experts in the nature and application of Twelve-
Step groups, will review the function and efficacy of these
groups, and define clinical indications for referral. They will
discuss the modality of Twelve-Step facilitation, a research-based
approach, wherein the clinician can help a patient understand
the value of participation in a Twelve-Step program, and facilitate
their engagement in the program in conjunction with professional
care. Examples from clinical practice will clarify the use of these
programs, and the presenters will have an exchange with
participants on clinical problems that are encountered in practice.
|
- Educational Objectives: Attendees at this session will gain an
increased understanding of the applicability of Twelve-Step
groups in addiction treatment and will improve their ability to
support engagement of their patients in Twelve-Step groups.
|
- Sponsored by: the Action Group on Twelve-Step Recovery
|
Session : ASAM802
COMPONENT SESSION II
Patient Placement Criteria Update: The PPC Supplement on Pharmacotherapies for Alcohol Use Disorders and Other New Directions
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 18.1 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Component Chair: Marc Fishman, MD
|
- Speakers: David Mee-Lee MD; George Kolodner MD
|
- Component Description: Over the past several years, the
number of pharmacotherapies for the treatment of alcohol use
disorders has grown, and their use has become increasingly
widespread. As new pharmacotherapeutic options emerge,
providers struggle with how these should be integrated with
psychosocial treatments, how they should be incorporated into
existing delivery models, and how their use should interact with
treatment planning and placement considerations. This session
will provide an introduction to the ASAM Patient Placement
Criteria Supplement on Pharmacotherapies for Alcohol Use
Disorders, which provides a guide for the field on incorporating
alcohol pharmacotherapies into practice and placement. The
session will also focus on the evolving role and use of the
ASAM PPC, along with future directions.
|
- Educational Objectives:
• To gain familiarity with the interactions between alcohol
pharmacotherapies, psychosocial treatments, and the ASAM
Patient Placement Criteria.
• To gain familiarity with new directions in the evolution of the
ASAM Patient Placement Criteria.
|
Session : ASAM803
COMPONENT SESSION III
Physicians-In-Training Committee
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 11.2 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Component Chair: Brian Hurley, MD
|
- Speaker: Claudia Arumala, MD
|
- Component Description: Physicians-In-Training increasingly
considering careers involving providing care for addictive
diseases. Much of this increase can be attributed to the work of
several programs exposing physicians-in-training to addiction
medicine earlier in their careers. Yet despite this interest, medical
education does not provide training in addiction care equivalent to many other diseases of comparable morbidity and mortality.
As such, many physicians-in-training go outside of their medical
school or residency program to obtain the training they need to
provide care to patients with substance use disorders.
Increasingly, there are opportunities to advocate for improved
training at the institution, state, and federal policy levels. Through
the American Society of Addiction Medicine, physicians-in-training
can become advocates for their own professional enhancement.
This three-part session will address the following: 1. The current
state of medical education on addiction medicine topics. 2. The
many opportunities for physicians-in-training that exist outside of
medical school and residency training, and 3. The ways students
can becoming involved with ASAM committees, and how that
committee work adds value to their development as physicians.
This session is sponsored by ASAM’s Physicians-In-Training
Committee – medical students, residents, program directors, and
medical educators are highly encouraged to participate.
|
- Educational Objectives: At the conclusion of the session,
participants will be able to:
✔ Understand the current status of incorporation of addiction
medicine principles in pre- and post-graduate medical
education
✔ Articulate the many training-enhancement opportunities for
medical students interested in addiction medicine careers.
✔ Identify the several opportunities for physician-in-training
members within the American Society of Addiction Medicine.
|
Session : ASAM804
COMPONENT SESSION IV
Opioid Maintenance Treatments
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 19.5 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Component Chair: Judith Martin, MD
|
- Component Description: Members of the opioid agonist
subworkgroup and the buprenorphine training subworkgroup
meet yearly at ASAM’s conference component session to share
creative work they are doing and to update each other on new
developments in the field. This year, we present information
about initiatives and mentoring in hepatitis and opioid
dependence treatment, updates on chronic pain management,
and review of known safety concerns regarding methadone
treatment, including cardiac risk and medication interactions.
|
- Educational Objectives:
At the end of this session, participants will be able to:
• Describe mentoring programs for physicians who treat opioid
dependence and hepatitis C.
• Describe management of chronic pain in patients on
maintenance treatments.
• Describe cardiac risk management in methadone maintenance.
|
Session : ASAM807
Opening Scientific Plenary and Distinguished Scientist Lecture
"Magnitude and Prevention of College age and Underage Drinking Problems"
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 16.3 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Ralph W. Hingson, Sc.D., M.P.H, Director of the Division of
Epidemiology and Prevention Research at the National Institute
on Alcohol Abuse and Alcoholism (NIAAA)
|
Session : ASAM808
SYMPOSIUM #1
Smoking Cessation in the Practice of Addiction Medicine
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 19.8 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Symposium Organizer: Ivan D. Montoya, MD, MPH
|
- Speakers: Kimber P. Richter, PhD, Maxine Stitzer, PhD; Bankole Johnson, MD, Tony George, MD; Steve Shoptaw, PhD, Eric Moolchan, MD; Dace Svikis, PhD; Himanshu Upadhyaya, MD; Douglas Ziedonis, MD
|
- Symposium Description: It has been reported that half of
individuals with alcohol dependence and two thirds with any drug
dependence have a nicotine dependence diagnosis. This high
co-morbidity may be due to biological, genetic, psychological,
and social factors. The high smoking rates may be the result of the
effect or withdrawal of the abused drug (self-medication
hypothesis) and/or a shared vulnerability to both disorders.
Furthermore, tobacco use may increase or attenuate the effects or
the withdrawal symptoms of the abused drug. Although tobacco
use is the leading preventable cause of morbidity and mortality in
people with addictive disorders, it is often overlooked by
addiction treatment providers for several reasons: 1) clinic staff
may smoke or have the misconception that drug addicts in
treatment should not quit smoking because they cannot handle
discontinuing multiple substance at the same time, and 2) lack of
trained personnel and resources to provide smoking cessation
services. Smoking cessation interventions during routine addiction
treatment practice can be very successful. Addiction treatment
providers should routinely screen for nicotine dependence and
include therapeutic strategies in their treatment plans. The purpose
of this symposium is to review the public health aspects of nicotine
dependence among patients with drug addiction, the bio-psychosocial
factors associated with smoking and drug use, the smoking
cessation approaches for this population, and ways of addressing
tobacco dependence in addiction treatment programs.
|
- Educational Objectives:
• To learn about the public health aspects of nicotine
dependence among patients with drug addiction
• To identify the bio-psycho-social factors associated with
smoking and drug use disorders
• To gain knowledge about the smoking cessation approaches
for individuals with substance use disorders who smoke.
• To recognize effective service strategies to address tobacco
dependence in addiction treatment programs.
|
- Sponsored by: The National Institute on Drug Abuse (NIDA)
|
Session : ASAM809
SYMPOSIUM #2
Better Living Through Chemistry: The Use of Drugs to Enhance Performance – On and Off the Field
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 20.1 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Symposium Organizer: Richard N. Rosenthal, MD
|
- Speakers: Mark S. Gold, MD; Alexandra G. Polles, MD; Laurence M. Westreich, MD; Richard N. Rosenthal, MD
|
- Symposium Description: This symposium will focus upon the use
of medical and illicit drugs to improve functioning in specific
areas. The use of chemical agents to improve performance has
been with us since ancient times, but only in recent times has
there been a consistent international effort aimed at evening the
playing field, such as the World Anti-Doping Agency. In addition
to their recreational use, athletes may use certain drugs of abuse
to improve performance. Over recent years, athletes’ use of
common and designer steroids has thrown a curve ball at home
run records and a monkey wrench into the wheels of cyclists’
achievements. These trends and some of the responses of the
field will be presented and discussed. But, performance
enhancement also has meaning off the field as well as on the
field. The use and abuse of medications for erectile dysfunction
will be presented as an example of performance enhancement
in the wider context of addictive behavior. Finally, the
philosophical and practical implications of using external means
to “do better” will be discussed (e.g. cosmetic surgery, erectile
dysfunction drugs, or psychotropic medications when there is no
medical diagnosis). In a competitive society where performance
can count a lot towards finding a mate, advancing salary or
career - where does one draw the line? What’s fair play?
|
- Educational Objectives:
At the conclusion of the symposium, participants should be
able to:
✔ understand the contribution of drugs of abuse and the influence
of steroids as performance enhancing agents for athletes
✔ discuss some of the responses of organized sports to the
problem of performance enhancement
✔ be familiar with performance enhancing agents that are
abused outside of the sports context
✔ discuss some of the important issues regarding beliefs and
values as they pertain to external means of performance
enhancement in American culture.
|
Session : ASAM810
PAPER SESSION 1
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 21.7 MB
|
Download Format(s) :
MP3 | |
|
|
|
- #1: Compassionate Coercion: Factors Associated With Court
Mandated Drug and Alcohol Treatment in Pregnancy,
1994-2005, Mishka Terplan, MD, MPH, Assistant
Professor, OB/GYN, University of Chicago, Chicago, IL
2008 Young Investigator Award Winner
|
- #2: Evaluation of Abuse-Potential of ALO-01, an Investigational
Abuse-Deterrent, Extended-Release Morphine Formulation
for Moderate-to-Severe Pain, James B. Jones, MD, PharmD,
FACEP, Alpharma Pharmaceuticals LLC, Piscataway, NJ
|
- #3: Acamprosate Efficacy in Alcohol-Dependent Patients:
Effects of Nicotine and Illicit Substance Use on Treatment
Outcomes, Barbara J. Mason, PhD, Professor, Committee
on the Neurobiology of Addictive Disorders, Director,
Laboratory of Clinical Psychopharmacology, Co-Director,
Pearson Center for Alcoholism and Addiction Research, The
Scripps Research Institute, La Jolla, CA
|
- #4: Involvement of Physicians in Community Treatment
Programs: Structural Barriers and Implications for the Use
of Pharmacotherapies, Lori J. Ducharme, PhD, Institute for
Behavioral, University of Georgia, Athens, GA
|
- #5: Characterization of Clinical Obsessive Compulsive
Disorder (OCD) in Methadone Maintenance Treatment
Patients: Females and Benzodiazepine Abuse, Einat Peles,
PhD, Adelson Clinic, Tel-Aviv Sourasky Medical Center,
Tel-Aviv, Israel
|
- #6: Survival Time in Rapid Opiate Detoxification, Yassini
Mojtaba, MD, Assistant Professor of Psychiatry, Yazd
Shahid Sadoughi University of Medical Sciences
|
- #7: Smoke-Free Policies in Addiction Treatment Facilities in
Ontario, Canada, Joan M. Brewster, PhD, Ontario
Tobacco Research Unit & Department of Public Health
Sciences, University of Toronto, Toronto, Ontario, Canada
|
Session : ASAM811
Course #1
The Hidden Wounds of Recovery: Addressing the Grief and Loss Processes in Recovery
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 19.1 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Course Organizer: James C. “Jes” Montgomery, MD
|
- Speakers: James C. Montgomery, MD; Ted Wiard, LPC; Rickey Dovers, MS
|
- Course Description: Much of the focus in early recovery is the
unmanageability of the addiction, the understanding of character
defects and the repair of the havoc that was wrought during the
acting out and using. For many in recovery one piece of work
that is often left untouched is the multifaceted healing process of
grief and loss. Remaining stuck in some aspect of the steps or in
anger or denial protects from the sadness and loss of reality. To
truly make amends to ones’ self, one must embrace losses that Recovery brings, finding the gifts within them. This course will
address the process of guiding recovering persons through
assessing attachments to the addiction, tremendous losses due to
it and the losses that come with the natural healing sacrifices of
Recovery. To recover and embrace spiritual healing requires not
only sacrifice, but also facing many realities; doing so means
grieving all hope of perfect families, secure futures, and certain
paths. The final component of this course will address processes
to guide recovering persons through assessing these losses,
actively pausing to grieve them, and preparing to move forward
with “life on life’s terms.”
|
- Educational Objectives: On completion of this presentation, the
attendee will:
✔ Have an understanding of the issues related to ongoing
grief in recovery.
✔ Have an understanding of the potential obstacles to recovery
that are posed by an arrested or incomplete grief process.
✔ Understand the process of the benefits and motivational skills
needed to guide the recovering person to embrace the painful
process of grief.
✔ Have an understanding of processes and tools to use to guide
the recovering person into and through this process.
|
- Intended audience: Beginners, Intermediate, Advanced.
|
Session : ASAM812
Workshop A
Opiate Replacement Treatment for Life? Differentiating Between Patient Candidates for Life-Time Maintenance vs. Maintenance-to-Abstinence Treatment
Conference : 39th Annual Medical-Scientifc Conference
Speaker(s) :
File Size : 17.6 MB
|
Download Format(s) :
MP3 | |
|
|
|
- Speakers: Thomas J. Brady, MD; Rocky Webb, MD; Mark Illuminati, MD; Maria Encarnacion, MD
|
- Workshop Description: Opiate replacement patients are currently
most often relegated to Methadone, or less so Buprenorphine,
for long-term treatment when many would benefit from a
Maintenance-to-Abstinence program lasting approximately 2-
years (+/- 1 year). Demographics are changing for patients with
opiate addiction – younger, fewer months and years dependent
on opiates, more prescription opiates than heroin, more oral and
less IV use. Relegating all or most patients with opiate addiction
to long-term opiate replacement medication may unintentionally
foster dependency and may risk supporting an addictive lifestyle
and perpetuate stigma (both external and internal) and patients’
low self-esteem. Employees in “traditional” methadone clinics
may mirror the psychology of the patient clientele; low morale
and job satisfaction, high turnover.
|
- A minority of OTP clinics admit all patients with opiate
dependence to a Maintenance-to- Abstinence track rather than a
Maintenance track. Such clinics buck tradition by treating opiate
replacement medication in no way as treatment in itself or cure,
but only as a tool to stabilize a patient so they can make use of co-existing disorders with the goal of treatment being eventual
abstinence in all but the most hard core, many years long,
multiple treatment failure patients.
In this workshop, several OTP clinic physicians’ experiences are
described, both from the perspective of pros and cons of
traditional opiate replacement maintenance treatment vs.
maintenance-to-abstinence treatment tracks. Criteria for
identifying patient candidates for the two groups will be
discussed. Additionally, treatment paradigm and clinic treatment
culture issues will be explored. Treatment team issues, such as
counselor skill sets, morale, and larger issues of public health and
treatment stigma will also be discussed.
|
- This workshop is designed for addiction psychiatrists, clinical directors
and counselors who are intermediate or advanced in the field.
|
- Educational Objectives: Upon completion of the workshop,
participants will be able to
✔ Improve differentiating between patient candidates for
lifetime Maintenance opiate replacement treatment vs.
Maintenance-to-Abstinence treatment.
✔ Better understand the barriers within and OTP clinic of
having the majority of patients’ assigned to Maintenanceto-
Abstinence treatment track.
✔ Have greater familiarity with the dangers for patients of
being directed to a Maintenance-to-Abstinence treatment
track such as relapse and communicable diseases.
|
|
|
| |
|
|
Showing sessions 1 - 10 of (33) TOTAL sessions
(PREV 10) 1 2 3 4 (NEXT 10)
|
All Libraries
|
